{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:57:38Z","timestamp":1762145858805,"version":"3.41.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-025-04867-6","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T03:32:50Z","timestamp":1748057570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of anticoagulants in elderly atrial fibrillation patients: a systematic review and network meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Xingran","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuanda","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linlin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengjiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"issue":"1","key":"4867_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.tcm.2021.12.001","volume":"33","author":"I Escudero-Mart\u00ednez","year":"2023","unstructured":"Escudero-Mart\u00ednez I, Morales-Caba L, Segura T. Atrial fibrillation and stroke: a review and new insights. Trends Cardiovasc Med. 2023;33(1):23\u20139.","journal-title":"Trends Cardiovasc Med"},{"issue":"2","key":"4867_CR2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.2174\/1871525713666150911112526","volume":"13","author":"RM da Silva","year":"2015","unstructured":"da Silva RM. Atrial fibrillation: epidemiology and peculiarities in the elderly. Cardiovasc Hematol Agents Med Chem. 2015;13(2):72\u20137.","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"issue":"8","key":"4867_CR3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","volume":"129","author":"SS Chugh","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129(8):837\u201347.","journal-title":"Circulation"},{"key":"4867_CR4","doi-asserted-by":"publisher","first-page":"101092","DOI":"10.1016\/j.arr.2020.101092","volume":"61","author":"L Bencivenga","year":"2020","unstructured":"Bencivenga L, Komici K, Nocella P, Grieco FV, Spezzano A, Puzone B, et al. Atrial fibrillation in the elderly: a risk factor beyond stroke. Ageing Res Rev. 2020;61:101092.","journal-title":"Ageing Res Rev"},{"issue":"5","key":"4867_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0002-9343(02)01236-6","volume":"113","author":"S Stewart","year":"2002","unstructured":"Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew\/Paisley study. Am J Med. 2002;113(5):359\u201364.","journal-title":"Am J Med"},{"issue":"9","key":"4867_CR6","doi-asserted-by":"publisher","first-page":"650","DOI":"10.7326\/M14-0538","volume":"161","author":"S Kalantarian","year":"2014","unstructured":"Kalantarian S, Ay H, Gollub RL, Lee H, Retzepi K, Mansour M, et al. Association between atrial fibrillation and silent cerebral infarctions: a systematic review and meta-analysis. Ann Intern Med. 2014;161(9):650\u20138.","journal-title":"Ann Intern Med"},{"issue":"38","key":"4867_CR7","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893\u2013962.","journal-title":"Eur Heart J"},{"issue":"12","key":"4867_CR8","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351.","journal-title":"N Engl J Med"},{"issue":"10","key":"4867_CR9","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391.","journal-title":"N Engl J Med"},{"issue":"11","key":"4867_CR10","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392.","journal-title":"N Engl J Med"},{"issue":"12","key":"4867_CR11","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","volume":"124","author":"N van Es","year":"2014","unstructured":"van Es N, Coppens M, Schulman S, Middeldorp S, B\u00fcller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124(12):1968\u201375.","journal-title":"Blood"},{"issue":"3","key":"4867_CR12","first-page":"301","volume":"66","author":"G Benedetti","year":"2018","unstructured":"Benedetti G, Neccia M, Agati L. Direct oral anticoagulants use in elderly patients with non valvular atrial fibrillation: state of evidence. Minerva Cardioangiol. 2018;66(3):301\u201313.","journal-title":"Minerva Cardioangiol"},{"key":"4867_CR13","doi-asserted-by":"publisher","first-page":"j5058","DOI":"10.1136\/bmj.j5058","volume":"359","author":"JA L\u00f3pez-L\u00f3pez","year":"2017","unstructured":"L\u00f3pez-L\u00f3pez JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ (Clinical Res ed). 2017;359:j5058.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"1","key":"4867_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1161\/STROKEAHA.117.018395","volume":"49","author":"M Proietti","year":"2018","unstructured":"Proietti M, Romanazzi I, Romiti GF, Farcomeni A, Lip GYH. Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke. 2018;49(1):98\u2013106.","journal-title":"Stroke"},{"key":"4867_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ijcard.2015.11.084","volume":"204","author":"GY Lip","year":"2016","unstructured":"Lip GY, Mitchell SA, Liu X, Liu LZ, Phatak H, Kachroo S, et al. Relative efficacy and safety of non-vitamin K oral anticoagulants for non-valvular atrial fibrillation: network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Int J Cardiol. 2016;204:88\u201394.","journal-title":"Int J Cardiol"},{"key":"4867_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3389\/fmed.2020.00107","volume":"7","author":"K Deng","year":"2020","unstructured":"Deng K, Cheng J, Rao S, Xu H, Li L, Gao Y. Efficacy and safety of direct oral anticoagulants in elderly patients with atrial fibrillation: a network meta-analysis. Front Med. 2020;7:107.","journal-title":"Front Med"},{"issue":"23","key":"4867_CR17","doi-asserted-by":"publisher","first-page":"e030380","DOI":"10.1161\/JAHA.123.030380","volume":"12","author":"DS Lin","year":"2023","unstructured":"Lin DS, Lo HY, Huang KC, Lin TT, Lee JK. Efficacy and safety of direct oral anticoagulants for stroke prevention in older patients with atrial fibrillation: a network meta-analysis of randomized controlled trials. J Am Heart Association. 2023;12(23):e030380.","journal-title":"J Am Heart Association"},{"key":"4867_CR18","first-page":"n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ (Clinical Res ed). 2021;372:n160.","journal-title":"BMJ (Clinical Res ed)"},{"key":"4867_CR19","first-page":"l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clinical Res ed). 2019;366:l4898.","journal-title":"BMJ (Clinical Res ed)"},{"key":"4867_CR20","doi-asserted-by":"crossref","unstructured":"Lee KH, Chen YF, Yeh WY, Yeh JT, Yang TH, Chou CY et al. Optimal stroke preventive strategy for patients aged 80 years or older with atrial fibrillation: a systematic review with traditional and network meta-analysis. Age Ageing. 2022;51(12).","DOI":"10.1093\/ageing\/afac292"},{"issue":"12","key":"4867_CR21","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/j.amjcard.2019.02.060","volume":"123","author":"AH Malik","year":"2019","unstructured":"Malik AH, Yandrapalli S, Aronow WS, Panza JA, Cooper HA. Meta-analysis of direct-acting oral anticoagulants compared with warfarin in patients\u2009>\u200975 years of age. Am J Cardiol. 2019;123(12):2051\u20137.","journal-title":"Am J Cardiol"},{"issue":"2","key":"4867_CR22","first-page":"175","volume":"67","author":"AJ McLachlan","year":"2012","unstructured":"McLachlan AJ, Pont LG. Drug metabolism in older people\u2013a key consideration in achieving optimal outcomes with medicines. Journals Gerontol Ser Biol Sci Med Sci. 2012;67(2):175\u201380.","journal-title":"Journals Gerontol Ser Biol Sci Med Sci"},{"issue":"12","key":"4867_CR23","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s40266-015-0318-1","volume":"32","author":"JL Tan","year":"2015","unstructured":"Tan JL, Eastment JG, Poudel A, Hubbard RE. Age-related changes in hepatic function: an update on implications for drug therapy. Drugs Aging. 2015;32(12):999\u20131008.","journal-title":"Drugs Aging"},{"issue":"5","key":"4867_CR24","first-page":"312","volume":"103","author":"N Shrikant Kulkarni","year":"2021","unstructured":"Shrikant Kulkarni N. Low-dose edoxaban effective for stroke prevention in older patients with atrial fibrillation. Am Family Phys. 2021;103(5):312\u20133.","journal-title":"Am Family Phys"},{"issue":"5","key":"4867_CR25","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s40256-024-00664-2","volume":"24","author":"SR Mandt","year":"2024","unstructured":"Mandt SR, Thadathil N, Klem C, Russ C, McNamee PL, Stigge K, et al. Apixaban use in patients with kidney impairment: a review of pharmacokinetic, interventional, and observational study data. Am J Cardiovasc Drugs: Drugs Devices Other Interventions. 2024;24(5):603\u201324.","journal-title":"Am J Cardiovasc Drugs: Drugs Devices Other Interventions"},{"issue":"22","key":"4867_CR26","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093\u2013104.","journal-title":"N Engl J Med"},{"issue":"1","key":"4867_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.tcm.2014.09.001","volume":"25","author":"JA Johnson","year":"2015","unstructured":"Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med. 2015;25(1):33\u201341.","journal-title":"Trends Cardiovasc Med"},{"key":"4867_CR28","doi-asserted-by":"crossref","unstructured":"Grze\u015bk G, Rogowicz D, Wo\u0142owiec \u0141, Ratajczak A, Gilewski W, Chudzi\u0144ska M et al. The clinical significance of drug-food interactions of direct oral anticoagulants. Int J Mol Sci. 2021;22(16).","DOI":"10.3390\/ijms22168531"},{"key":"4867_CR29","doi-asserted-by":"crossref","unstructured":"Saviano A, Brigida M, Petruzziello C, Candelli M, Gabrielli M, Ojetti V. Gastrointestinal bleeding due to NOACs use: exploring the molecular mechanisms. Int J Mol Sci. 2022;23(22).","DOI":"10.3390\/ijms232213955"},{"issue":"11","key":"4867_CR30","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1007\/s00277-018-3364-z","volume":"97","author":"M Peverelle","year":"2018","unstructured":"Peverelle M, Asadi K, Sinclair M. Drug-induced liver failure due to rivaroxaban. Ann Hematol. 2018;97(11):2267\u20138.","journal-title":"Ann Hematol"},{"issue":"21","key":"4867_CR31","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1093\/eurheartj\/ehp384","volume":"30","author":"AJ Camm","year":"2009","unstructured":"Camm AJ. The RE-LY study: randomized evaluation of long-term anticoagulant therapy: dabigatran vs. warfarin. Eur Heart J. 2009;30(21):2554\u20135.","journal-title":"Eur Heart J"},{"issue":"1","key":"4867_CR32","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12872-017-0511-8","volume":"17","author":"PK Bundhun","year":"2017","unstructured":"Bundhun PK, Chaudhary N, Yuan J. Bleeding events associated with a low dose (110\u00a0mg) versus a high dose (150\u00a0mg) of Dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2017;17(1):83.","journal-title":"BMC Cardiovasc Disord"},{"issue":"4","key":"4867_CR33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s13181-011-0178-y","volume":"7","author":"M Ganetsky","year":"2011","unstructured":"Ganetsky M, Babu KM, Salhanick SD, Brown RS, Boyer EW. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicology: Official J Am Coll Med Toxicol. 2011;7(4):281\u20137.","journal-title":"J Med Toxicology: Official J Am Coll Med Toxicol"},{"key":"4867_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1756-8722-4-53","volume":"4","author":"S Redondo","year":"2011","unstructured":"Redondo S, Mart\u00ednez MP, Ramajo M, Navarro-Dorado J, Barez A, Tejerina T. Pharmacological basis and clinical evidence of dabigatran therapy. J Hematol Oncol. 2011;4:53.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4867_CR35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12245-024-00677-3","volume":"17","author":"R Matbouli","year":"2024","unstructured":"Matbouli R, Pantet O, Castioni J, Vakilzadeh N, Alberio L, Hugli O. Dabigatran accumulation in acute kidney injury: is more better than less to prevent bleeding? A case report. Int J Emerg Med. 2024;17(1):91.","journal-title":"Int J Emerg Med"},{"issue":"10","key":"4867_CR36","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1007\/s12325-023-02544-8","volume":"40","author":"K Hahn","year":"2023","unstructured":"Hahn K, Lamparter M. Prescription of DOACs in patients with atrial fibrillation at different stages of renal insufficiency. Adv Therapy. 2023;40(10):4264\u201381.","journal-title":"Adv Therapy"},{"issue":"1","key":"4867_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12325-022-02333-9","volume":"40","author":"S Ballestri","year":"2023","unstructured":"Ballestri S, Romagnoli E, Arioli D, Coluccio V, Marrazzo A, Athanasiou A, et al. Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative review. Adv Therapy. 2023;40(1):41\u201366.","journal-title":"Adv Therapy"},{"issue":"12","key":"4867_CR38","first-page":"748","volume":"101","author":"AR Roth","year":"2020","unstructured":"Roth AR, Lazris A, Haskell H, James J. Anticoagulation in older adults. Am Family Phys. 2020;101(12):748\u201350.","journal-title":"Am Family Phys"},{"issue":"1","key":"4867_CR39","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/asheducation-2016.1.188","volume":"2016","author":"C Ribic","year":"2016","unstructured":"Ribic C, Crowther M. Thrombosis and anticoagulation in the setting of renal or liver disease. Hematol Am Soc Hematol Educ Program. 2016;2016(1):188\u201395.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"4867_CR40","doi-asserted-by":"crossref","unstructured":"Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European society of cardiology. 2018;20(8):1231\u201342.","DOI":"10.5603\/KP.2018.0180"},{"issue":"9","key":"4867_CR41","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40266-024-01138-5","volume":"41","author":"JR Spruit","year":"2024","unstructured":"Spruit JR, de Vries TAC, Hemels MEW, Pisters R, de Groot JR, Jansen R. Direct oral anticoagulants in older and frail patients with atrial fibrillation: a decade of experience. Drugs Aging. 2024;41(9):725\u201340.","journal-title":"Drugs Aging"},{"issue":"7","key":"4867_CR42","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1111\/jce.16308","volume":"35","author":"S Mohanty","year":"2024","unstructured":"Mohanty S, Torlapati PG, La Fazia VM, Kurt M, Gianni C, MacDonald B, et al. Best anticoagulation strategy with and without appendage occlusion for stroke-prophylaxis in postablation atrial fibrillation patients with cardiac amyloidosis. J Cardiovasc Electrophys. 2024;35(7):1422\u20138.","journal-title":"J Cardiovasc Electrophys"},{"issue":"6","key":"4867_CR43","doi-asserted-by":"publisher","first-page":"625","DOI":"10.23736\/S2724-5683.24.06546-3","volume":"72","author":"C Lavalle","year":"2024","unstructured":"Lavalle C, Pierucci N, Mariani MV, Piro A, Borrelli A, Grimaldi M, et al. Italian registry in the setting of atrial fibrillation ablation with rivaroxaban - IRIS. Minerva Cardiol Angiol. 2024;72(6):625\u201337.","journal-title":"Minerva Cardiol Angiol"},{"issue":"1","key":"4867_CR44","first-page":"12","volume":"24","author":"L Branca","year":"2023","unstructured":"Branca L, Tomasoni D, Cimino G, Cersosimo A, Lombardi CM, Chizzola G, et al. Impact and predictors of device-related thrombus after percutaneous left atrial appendage closure. J Cardiovasc Med (Hagerstown Md). 2023;24(1):12\u20139.","journal-title":"J Cardiovasc Med (Hagerstown Md)"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04867-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-04867-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04867-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T03:32:53Z","timestamp":1748057573000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-04867-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4867"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-04867-6","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]},"assertion":[{"value":"15 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a systematic review and meta-analysis, ethics approval and consent to participate are not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This study does not involve human participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"396"}}